MiNK Therapeutics, Inc. Common Stock (INKT) is a publicly traded Healthcare sector company. As of May 21, 2026, INKT trades at $10.29 with a market cap of $50.02M and a P/E ratio of -3.67. INKT moved +4.15% today. Year to date, INKT is -11.11%; over the trailing twelve months it is +48.60%. Its 52-week range spans $4.56 to $76.00. Analyst consensus is buy with an average price target of $35.00. Rallies surfaces INKT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
MiNK Therapeutics Opens 90-Patient Phase II ARDS Trial with H2 2026 Readouts: MiNK Therapeutics launched a randomized Phase II ARDS trial enrolling 90 patients 1:1 with endpoints of overall survival, ventilator-free days and ICU days, and expects early readouts in the second half of 2026. It has an INKT cell manufacturing process and is combining its therapy with Immunity Bio’s IL-15 superagonist Antiva targeting fungal pneumonia.
| Metric | Value |
|---|---|
| Price | $10.29 |
| Market Cap | $50.02M |
| P/E Ratio | -3.67 |
| EPS | $-2.93 |
| Dividend Yield | 0.00% |
| 52-Week High | $76.00 |
| 52-Week Low | $4.56 |
| Volume | 32 |
| Avg Volume | 0 |
| Revenue (TTM) | $180.25K |
| Net Income | $-12.49M |
| Gross Margin | 0.00% |
1 analysts cover INKT: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $35.00.